Ketek ™ (Telithromycin) NDA 21-144 Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products.

Slides:

Advertisements

Similar presentations

Antimicrobial Prescribing in the Management of COPD

Advertisements

AFRT 8 nov 2002 A3-1 Why Another Antibiotic for Respiratory Tract Infections? C. Couturier.

Acute Otitis Media Trials: Evolution of Guidance Janice Soreth, M.D. Division of Anti-Infective Drug Products January 30, 2001.

The Resistance Problem PRSP = Penicillin Resistant Strep. pneumoniae QRSP = Quinolone Resistant Strep. pneumoniae MRSA = Methicillin Resistant Staph.

Telithromycin Integrated Summary of Safety Anti-Infective Drugs Advisory Committee January 8, 2003 Charles Cooper, M.D. Medical Officer Division of Anti-Infective.

Primary bloodstream infection as an indication: Regulatory perspective FDA/IDSA/ISAP Workshop April 15, 2004 David Ross, M.D., Ph.D.

1 Issues in Selection of Deltas in Non-Inferiority Trials : Acute Bacterial Meningitis and Hospital- Acquired Pneumonia John H. Powers, M.D. Medical Officer.

Judicious Antibiotic Use in Developing Countries Global Missions Health Conference Louisville, KY Nov. 9, 2012 Ron Herman, Ph.D.

 Cefixime is quickly establishing in Western countries as a potent broad-spectrum antibiotic with a variety of indications. A multinational, nonrandomized.

Community- acquired Pneumonia Author Dr. Shek Kam Chuen Oct 2013 HKCEM College Tutorial.

بنام خداوند جان وخرد. Dr. Alireza Emami Naeini Associate Prof. Department of Infectious Diseases Isfahan University of Medical Sciences(IUMS) Empiric.

Augmentin® ES Clinical Microbiology Review

Challenges in Antibacterial Drug Development Francis P. Tally M.D. Cubist Pharmaceuticals, Inc.

Office of Drug Evaluation IV, CDER FDA/IDSA/ISAP Workshop 4/16/04 Overview of PK-PD in Drug Development Programs: FDA Perspective FDA/IDSA/ISAP Workshop.

C-1 Staphylococcus aureus Bacteremia and Endocarditis: A Bad Bug and A New Drug G. Ralph Corey M.D. Professor of Internal Medicine and Infectious Diseases.

Michael R. Jacobs, MD, PhD Professor of Pathology and Medicine Case Western Reserve University Director of Clinical Microbiology University Hospitals of.

Macrolide-Resistant Streptococcus pneumoniae: What is the Public Health Impact? John H. Powers, M.D. Lead Medical Officer Antimicrobial Drug Development.

1 Zyvox™ (linezolid) Tablets, injection, suspension NDAs , , FDA presentation Anti-Infective Drugs Advisory Committee March 24, 2000.

Giebink – FDA – 01/2001 Otitis Media Epidemiology and Drug-Resistant Streptococcus pneumoniae G. Scott Giebink, M.D. Professor of Pediatrics and Otolaryngology.

1 Hepatic Effects of Ketek (Telithromycin) Edward Cox, MD, MPH Medical Officer FDA.

MM-1 FDA Advisory Committee April 26, 2001 KETEK ™ (telithromycin)

IDSA / ISAP / FDA Workshop on Antimicrobial Drug Development Update 2004 Edward Cox, MD MPH ODE IV Center for Drug Evaluation and Research US Food and.

1 Factive ® (gemifloxacin) NDA March 4, 2003 Anti Infective Drugs Advisory Committee Meeting Edward Cox, M.D., M.P.H. Deputy Director, Office of.

Factors Leading to the Spread of Vancomycin-Resistant Enterococci in US Hospitals Factors Antimicrobial pressure Environmental contamination and survival.

Aventis KETEK_AC2 26-May-16 Main Presentation Version 6-5 MM-1 FDA Advisory Committee January 8, 2003 KETEK ™ (telithromycin) Aventis Pharmaceuticals.

Development of Antibiotics for Otitis Media: Past, Present, and Future Janice Soreth, M.D. Director Division of Anti-Infective Drug Products.

Respiratory Tract infections. PROF. AzzA ELMedany Department of pharmacology.

Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS.

Augmentin ES  for acute otitis media Mamodikoe Makhene, M.D. Prepared for Anti-infectives Advisory Committee meeting January 30, 2001.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

Anti-Infective Drugs Advisory Committee Meeting December 15, Data Mining Analysis of Multiple Antibiotics in AERS Jonathan G. Levine, PhD Mathematical.

Giebink – FDA – 07/11/02 Design Issues in Antimicrobial Treatment Trials of AOM G. Scott Giebink, M.D. Professor of Pediatrics and Otolaryngology Director,

Issues with Effectiveness, Resistance and Ethics in Antimicrobial Clinical Trials How We Can Do Better Issues with Effectiveness, Resistance and Ethics.

Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.

PK/PD of Antibiotics in relation to resistance Otto Cars MD Department of Medical Sciences Infectious diseases Uppsala University Sweden.

AI Study  Design SOF 1W then DCV + SOF 23W DVC + SOF Randomisation* 1 : 1 : 1 Open-label AI Study: DCV + SOF + RBV for genotypes 1, 2 and.

How Clinicians Use Data For Clinical Decision Making March 5, 2003 Anti-Infective Drug Advisory Committee How Clinicians Use Data For Clinical Decision.

Center for Drug Evaluation and Research Anti-Infective Drug Advisory Committee March 6, New Drug Application NDA /S-008 Cubicin® (daptomycin.

Antimicrobial Resistance in Streptococcus pneumoniae Implications for Prescription Drug Labeling John H. Powers, MD Lead Medical Officer Antimicrobial.

1 Observations from Past Approvals for Acute Bacterial Sinusitis Janice Pohlman, M.D. AIDAC Meeting, October 29, 2003.

Michael R. Jacobs, MD, PhD FDA Presentation Nov 7, 2001

When Blood & Guidance Go Bad: The Story of Bacteremia as an Indication Janice Soreth, M.D. Director Division of Anti-Infective Drugs US Food & Drug Administration.

Joint Meeting of the Anti-Infective Drugs Advisory Committee and the Drug Safety and Risk Management Committee Meeting December 14 & 15, Anti-Infective.

Clinical Trials of Acute Otitis Media John Alexander, M.D., M.P.H. Anti-Infective Drugs Advisory Committee November 7, 2001.

Acute Otitis Media: Lessons Learned Thomas Smith, M.D. Division of Anti-Infective Drug Products.

Center for Drug Evaluation and Research March 6, 2005 Bacteremia and Endocarditis: Products and Guidance Janice Soreth, MD Director Division of Anti-Infective.

Anti-Infective Drugs Advisory Committee Meeting September 12, Factive® (gemifloxacin) Proposed for the treatment of Acute Bacterial Sinusitis Oscient.

Ketek  (telithromycin) NDA Background Janice Soreth, M.D. Director Division of Anti-Infective Drug Products CDER/FDA.

In the Best Interests of the Public Health... Janice Soreth, M.D. Acting Director Division of Anti-Infective Drug Products CDER/FDA.

1 Antibiotic Resistance: An Update Janice Soreth, M.D. Director Division of Anti-Infective Drug Products February 20, 2002.

Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,

Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA.

David M. Shlaes Anti-infectives Consulting, LLC Stonington, CT Participation sponsored by: Nabriva, Vienna, AU Novexel, Romainville, FR Consulting relationships.

1 Zithromax  (Azithromycin) Oral Suspension Single-Dose & 3-day Treatment of Acute Otitis Media Anti-Infective Drugs Advisory Committee November 7, 2001.

1 Developing drugs for resistant pathogens: Problems and possibilities David Ross, M.D., Ph.D. Anti-Infective Drugs Advisory Committee February 20, 2002.

CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.

1 Issues in Conduct of Catheter Related Infection (CRI) Studies Charles Knirsch, MD, MPH FDA Anti-infective Advisory Committee Meeting October 14, 2004.

Table 3 Clinical response success rate, according to prior effective antimicrobial therapy in hospitalized patients with community-acquired pneumonia given.

In vitro susceptibility of S

Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.

Number of S, I and R to six antibiotics

Meta-Analysis of a Possible Signal of Increased Mortality Associated with Cefepime Use Peter W. Kim, Yu-te Wu, Charles Cooper, George Rochester, Thamban.

R. Leclercq Clinical Microbiology and Infection

E. Monee’ Carter-Griffin DNP, RN, ACNP-BC

Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting Jeffrey Paul.

Expert Insights on Complex Clinical Cases of Edema

D.E. Low Clinical Microbiology and Infection

Decreasing rates of resistance to penicillin, but not erythromycin, in Streptococcus pneumoniae after introduction of a policy to restrict antibiotic.

J. Garau Clinical Microbiology and Infection

Evaluation of 5-day therapy with telithromycin, a novel ketolide antibacterial, for the treatment of tonsillopharyngitis S.R. Norrby, J. Quinn, M. Rangaraju,

Presentation transcript:

Ketek ™ (Telithromycin) NDA Efficacy Review John Alexander, M.D., M.P.H. Medical Team Leader Division of Anti-Infective Drug Products

Outline Indications –Original NDA Studies –Resubmission Studies Drug-Resistant Streptococcus pneumoniae –Penicillin Resistance –Erythromycin Resistance

Indications Acute Exacerbation of Chronic Bronchitis Acute Sinusitis Community-Acquired Pneumonia Tonsillitis/Pharyngitis

Acute Exacerbation of Chronic Bronchitis Two Studies with the Original NDA –Study 3003 –Telithromycin for 5 days –Amox/Clav 500mg/125mg TID for 10 days –Study 3007 –Telithromycin for 5 days –Cefuroxime Axetil 500 mg BID for 10 days One Study in the Resubmission –Study 3013 –Telithromycin for 5 days –Clarithromycin 500 mg BID for 10 days

Acute Exacerbation of Chronic Bronchitis

Acute Sinusitis Three Studies with 1st Review Cycle –Study 3002 –Telithromycin for 5 days or 10 days, uncontrolled –Study 3005 –Telithromycin for 5 days or 10 days –Amox/Clav 500mg/125mg TID for 10 days –Study 3011 –Telithromycin for 5 days –Cefuroxime Axetil 250 mg BID for 10 days No New Studies in the Resubmission

Acute Sinusitis

Community-Acquired Pneumonia Original NDA Studies –Study 3001 –Telithromycin for 10 days –Amoxicillin 1g TID for 10 days –Study 3006 –Telithromycin for 10 days –Clarithromycin 500 mg BID for 10 days –Study 3009 –Telithromycin for 7-10 days –Trovafloxacin 200 mg QD for 7-10 days –Open-Label Studies 3000, 3009OL, 3010

Community-Acquired Pneumonia

New Studies in the Resubmission –Study 4003 –Telithromycin for 5 days or 7 days –Clarithromycin 500 mg BID for 10 days –Study 3012 –Open-label, Telithromycin for 7 days Japanese Studies –Study 3107 and Study 2105

Drug-Resistant S. pneumoniae Clinical Cases with DRSP Collected from CAP and AS Studies –Penicillin Resistance (MIC  2  g/mL) –Erythromycin Resistance (MIC  1  g/mL)

CAP: Drug-Resistant S. pneumoniae Telithromycin MIC

CAP: Drug-Resistant S. pneumoniae A Total of 49 Cases of CAP due to DRSP from Western Studies Subset of Bacteremic Cases Additional Cases from Japanese Trials

CAP: Drug-Resistant S. pneumoniae

Non-evaluable Patients –5 Successes –2 Failures –5 Indeterminate Withdrawn for Elevated BUN/CR on Day 6 Bronchitis at TOC visit, Aspiration on Day 5, New Antibiotics on Day 3 (AE and baseline bacteremia), Withdrawal for Personal Reasons

CAP: Drug-Resistant S. pneumoniae All PRSP: –19/27 (70.4%) in MITT, 1 Indeterminate All ERSP: –29/37 (78.4%) in MITT 7 Comparator Patients with DRSP –2 Isolates Susceptible to Comparator Agent –3/5 in Clarithromycin Patients with ERSP

CAP: Drug-Resistant S. pneumoniae Bacteremia Patients

CAP: Drug-Resistant S. pneumoniae Cases from Japanese Studies

AS: Drug-Resistant S. pneumoniae A Total of 29 Cases of Acute Sinusitis due to DRSP Includes both 5-day and 10-day Duration All cases from Studies in Original NDA

AS: Drug-Resistant S. pneumoniae

Acknowledgments Statistical –Thamban Valappil, Ph. D. –George Rochester, Ph. D. Clinical –Alma Davidson, M. D. –Janice Soreth, M. D. Project Management –Judit Milstein Ketek Review Team